Prognostic Value of Selected Epithelial‐Mesenchymal Transition and Immune Checkpoint Markers in Predicting Malignant Transformation of Oral Leukoplakia
Journal of Oral Pathology & Medicine · 2026-11 · 55 (10) · 1162-1172
DOI: 10.1111/jop.70187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, online erschienen am 27.09.2026. Verfasst von Jiveswara Vijiakumar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Leukoplakia, Oral, Epithelial-Mesenchymal Transition, Cell Transformation, Neoplastic, Biomarkers, Tumor. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Ministry of Higher Education, Malaysia.
Abstract (Originalsprache)
Aim
This study investigates the prognostic potential of epithelial‐mesenchymal transition (EMT) markers (E‐cadherin, N‐cadherin, Twist) and immune checkpoint markers (PD‐1, PD‐L1) in predicting malignant transformation (MT) of oral leukoplakia (OL). Methodology Immunohistochemistry (IHC) was performed on 56 OL tissue samples, categorized equally into progressive (transformed to higher‐grade dysplasia or OSCC within 3 years) and non‐progressive groups. Expression levels of E‐cadherin, N‐cadherin, Twist, PD‐1, and PD‐L1 were systematically assessed.
Results
Progressive OL cases showed descriptive trends of lower E‐cadherin expression, higher N‐cadherin and Twist expression compared with non‐progressive cases; however, these EMT‐marker differences were not statistically significant. PD‐1 expression was significantly higher in progressive OL ( p = 0.038) compared with non‐progressive OL. When stratified into non‐progressive, dysplasia‐progressive, and OSCC‐progressive subsets, PD‐L1 expression demonstrated significant variation ( p = 0.018). Higher PD‐1 expression was significantly associated with progressive OL in males ( p = 0.02) and correlated with a shorter time to progression (τb = 0.456, p = 0.004).
Conclusion
The findings suggest that immune checkpoint markers, particularly PD‐1 and PD‐L1, may be associated with progression in OL and may warrant further validation as adjunctive prognostic markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, Malaysia.
- Oral Cancer Research & Coordinating Centre (OCRCC), Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, Malaysia.
- RAK Collage of Dental Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE.
- Faculty of Dental Sciences, University of Peradeniya, Sri Lanka.
ORCID-Profile: Jiveswara Vijiakumar, Thomas George Kallarakkal, Lee Peng Karen-Ng, Samadara Siriwardena, Wanninayake Mudiyanselage Tilakaratne
Förderung
- Ministry of Higher Education, Malaysia
Zitieren
APA
Vijiakumar, J., Kallarakkal, T. G., Karen-Ng, L. P., Siriwardena, S., & Tilakaratne, W. M. (2026). Prognostic Value of Selected Epithelial‐Mesenchymal Transition and Immune Checkpoint Markers in Predicting Malignant Transformation of Oral Leukoplakia. Journal of Oral Pathology & Medicine, 55(10), 1162-1172. https://doi.org/10.1111/jop.70187
Vancouver
Vijiakumar J, Kallarakkal TG, Karen-Ng LP, Siriwardena S, Tilakaratne WM. Prognostic Value of Selected Epithelial‐Mesenchymal Transition and Immune Checkpoint Markers in Predicting Malignant Transformation of Oral Leukoplakia. Journal of Oral Pathology & Medicine. 2026;55(10):1162-1172. doi:10.1111/jop.70187
BibTeX
@article{Vijiakumar2026,
author = {Vijiakumar, Jiveswara and Kallarakkal, Thomas George and Karen-Ng, Lee Peng and Siriwardena, Samadara and Tilakaratne, Wanninayake Mudiyanselage},
title = {Prognostic Value of Selected Epithelial‐Mesenchymal Transition and Immune Checkpoint Markers in Predicting Malignant Transformation of Oral Leukoplakia},
journal = {Journal of Oral Pathology & Medicine},
year = {2026},
volume = {55},
number = {10},
pages = {1162--1172},
doi = {10.1111/jop.70187}
}
EUVIMED